Clinical Trials

If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.
Title: A Phase 2, Dose-finding, Randomized,
Double-blind, Placebo-controlled, Multicenter
Study to Evaluate the Safety and Efficacy of
Efavaleukin Alfa Induction Therapy in Subjects
with Moderately to Severely Active Ulcerative
Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Matthew Lincoln, DO
Sponsors: Amgen
Details (Indentifier #): 04987307
Title: CHS1221: A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Michael J Georgetson, MD, FACG, FASGE
Sponsors: Cristcot
Details (Indentifier #): NCT04469686
Title: Cultivate-APD334-202: A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Michael J Georgetson, MD, FACG, FASGE
Sponsors: Arena
Details (Indentifier #): NCT04173273
Title: Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Michael J Georgetson, MD, FACG, FASGE
Sponsors: Seres
Details (Indentifier #): NCT02437500
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Thomas J McDonald, MD
Sponsors: Janssen
Details (Indentifier #): none
Title: M20-259: A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Michael J Georgetson, MD, FACG, FASGE
Sponsors: AbbVie
Details (Indentifier #): NCT04524611